Annex

United Kingdom

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

in Part 1, the heading of point 1.1.1.4 is replaced by the following:

‘ Chemical name ’;

(2)

in Part 3, Table 3.1 is amended as follows:

(a)

the title of the second column is replaced by the following: ‘Chemical name’;
(b)
the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)
1. (*)
  
  ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;
(c)

the entry corresponding to index number 607-414-00-6 is deleted;

(d)

the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATEs	Notes
Index No	Chemical name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors and ATEs	Notes
‘006-044-00-7	isoproturon (ISO); 3-(4-isopropylphenyl)-1,1-dimethylurea	251-835-4	34123-59-6	Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H373 (blood) H400 H410	GHS08 GHS09 Wng	H351 H373 (blood) H410		M = 10 M = 10’
‘015-101-00-5	phosmet (ISO); S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate; O,O-dimethyl-S-phthalimidomethyl phosphorodithioate	211-987-4	732-11-6	Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1	H361f H332 H301 H370 (nervous system) H400 H410	GHS08 GHS06 GHS09 Dgr	H361f H332 H301 H370 (nervous system) H410		M = 100 M = 100’
‘016-096-00-2	thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate	—	79277-27-3	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 100 M = 100’
‘017-011-00-1	sodium hypochlorite, solution … % Cl active	231-668-3	7681-52-9	Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H314 H318 H400 H410	GHS05 GHS09 Dgr	H314 H410	EUH031	M = 10 M = 1 EUH031: C ≥ 5 %	B’
‘025-002-00-9	potassium permanganate	231-760-3	7722-64-7	Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1	H272 H361d H302 H400 H410	GHS03 GHS08 GHS07 GHS09 Dgr	H272 H361d H302 H410’
‘603-180-00-4	colecalciferol; cholecalciferol; vitamin D₃	200-673-2	67-97-0	Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1	H330 H310 H300 H372	GHS06 GHS08 Dgr	H330 H310 H300 H372		inhalation: ATE = 0,05 mg/L (dusts or mists) dermal: ATE = 50 mg/kg bw oral: ATE = 35 mg/kg bw STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 %’
‘604-014-00-3	chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol	200-431-6	59-50-7	Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3	H302 H314 H318 H335 H317 H400 H412	GHS07 GHS05 GHS09 Dgr	H302 H314 H335 H317 H410		M = 1’
‘604-016-00-4	1,2-dihydroxybenzene; pyrocatechol	204-427-5	120-80-9	Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2	H350 H341 H311 H301 H315 H319	GHS08 GHS06 Dgr	H350 H341 H311 H301 H315 H319		oral: ATE = 300 mg/kg bw dermal: ATE = 600 mg/kg bw’
‘604-090-00-8	4-tert-butylphenol	202-679-0	98-54-4	Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1	H361f H315 H318 H410	GHS08 GHS05 GHS09 Dgr	H361f H315 H318 H410		M = 1’
‘605-003-00-6	acetaldehyde; ethanal	200-836-8	75-07-0	Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2	H224 H350 H341 H335 H319	GHS02 GHS08 GHS07 Dgr	H224 H350 H341 H335 H319’
‘606-047-00-9	2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone	404-360-3	119313-12-1	Repr. 1B Aquatic Acute 1 Aquatic Chronic 1	H360D H400 H410	GHS08 GHS09 Dgr	H360D H410’
‘607-096-00-9	maleic anhydride	203-571-6	108-31-6	Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A	H302 H372 (respiratory system) (inhalation) H314 H318 H334 H317	GHS07 GHS08 GHS05 Dgr	H302 H372 (respiratory system) (inhalation) H314 H334 H317	EUH071	Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-103-00-5	succinic anhydride	203-570-0	108-30-5	Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1	H302 H314 H318 H334 H317	GHS07 GHS05 GHS08 Dgr	H302 H314 H334 H317	EUH071’
‘607-113-00-X	isobutyl methacrylate	202-613-0	97-86-9	Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B	H226 H335 H315 H317	GHS02 GHS07 Wng	H226 H335 H315 H317			D’
‘607-373-00-4	quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate	414-200-4	200509-41-7	Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H361fd H302 H373 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361fd H302 H373 H410		M = 1 M = 1’
‘613-167-00-5	reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)	—	55965-84-9	Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H310 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H310 H301 H314 H317 H410	EUH071	Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100	B’
‘613-205-00-0	propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole	262-104-4	60207-90-1	Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H302 H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H317 H410		M = 1 M = 1’
‘614-001-00-4	nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine	200-193-3	54-11-5	Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2	H330 H310 H300 H411	GHS06 GHS09 Dgr	H330 H310 H300 H411		inhalation: ATE = 0,19 mg/L (dusts or mists) dermal: ATE = 70 mg/kg bw oral: ATE = 5 mg/kg bw’

(e)

the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATEs	Notes
Index No	Chemical name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors and ATEs	Notes
‘604-094-00-X	isoeugenol; [1] (E)-2-methoxy-4-(prop-1-enyl)phenol; [2] (Z)-2-methoxy-4-(prop-1-enyl)phenol [3]	202-590-7 [1] 227-678-2 [2] 227-633-7 [3]	97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3]	Skin Sens. 1A	H317	GHS07 Wng	H317		Skin Sens. 1A; H317: C ≥ 0,01 %’
‘607-724-00-1	2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin	—	240494-71-7	Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H370 (nervous system) H373 H400 H410	GHS06 GHS08 GHS09 Dgr	H332 H301 H370 (nervous system) H373 H410		M = 100 M = 100’
‘607-725-00-7	isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene	—	65733-16-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘607-726-00-2	pinoxaden (ISO); 8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate	—	243973-20-8	Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3	H361d H332 H302 H319 H335 H317 H400 H412	GHS08 GHS07 GHS09 Wng	H361d H332 H302 H319 H335 H317 H410		inhalation: ATE = 4,63 mg/L (dusts or mists) oral: ATE = 500 mg/kg bw M = 1’
‘607-727-00-8	tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate	231-711-6	7696-12-0	Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H302 H371 (nervous system) (inhalation) H400 H410	GHS08 GHS07 GHS09 Wng	H351 H302 H371 (nervous system) (inhalation) H410		M = 100 M = 100’
‘607-728-00-3	(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate	214-619-0	1166-46-7	Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H302 H371 (nervous system) (inhalation) H400 H410	GHS08 GHS07 GHS09 Wng	H351 H302 H371 (nervous system) (inhalation) H410		M = 100 M = 100’
‘607-729-00-9	mesosulfuron-methyl (ISO); methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;	—	208465-21-8	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 100 M = 100’
‘607-730-00-4	spirodiclofen (ISO); 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate	—	148477-71-8	Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1	H350 H361f H373 H317 H410	GHS08 GHS07 GHS09 Dgr	H350 H361f H373 H317 H410		M = 10’
‘607-731-00-X	sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium	218-953-8	2302-17-2	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M = 1 M = 1’
‘607-732-00-5	salicylic acid	200-712-3	69-72-7	Repr. 2 Acute Tox. 4 Eye Dam. 1	H361d H302 H318	GHS08 GHS07 GHS05 Dgr	H361d H302 H318’
‘608-068-00-9	flutianil (ISO); (2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile	—	958647-10-4	Aquatic Chronic 1	H410	GHS09 Wng	H410		M = 100’
‘612-293-00-8	reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine	447-920-2	-	Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1	H361f H302 H314 H318	GHS08 GHS07 GHS05 Dgr	H361f H302 H314	EUH071’
‘613-326-00-9	2-methylisothiazol-3(2H)-one	220-239-6	2682-20-4	Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS05 GHS06 GHS09 Dgr	H330 H311 H301 H314 H317 H410	EUH071	Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1’
‘613-327-00-4	pyroxsulam (ISO); N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide	—	422556-08-9	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M = 100 M = 100’
‘613-328-00-X	1-vinylimidazole	214-012-0	1072-63-5	Repr. 1B	H360D	GHS08 Dgr	H360D		Repr. 1B; H360D: C ≥ 0,03 %’
‘616-224-00-2	amisulbrom (ISO); 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide	—	348635-87-0	Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H319 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H319 H410		M = 10 M = 10’